CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study Apr 27, 2023 8:45am EDT
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Apr 10, 2023 8:45am EDT
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Apr 06, 2023 9:05am EDT
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update Apr 03, 2023 8:05am EDT
CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues Mar 13, 2023 7:05am EDT
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland Mar 09, 2023 9:05am EST
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Feb 07, 2023 8:45am EST
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland Jan 12, 2023 8:45am EST
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event Jan 05, 2023 9:05am EST
